Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) Stock Price: $82.20+3.38 (+4.29%)

The total return cagr for Zoetis Inc. (ZTS) stock is -49.31% over the past 12 months. The 3 year average growth rate is -19.45% and the 5 year cagr is -13.32%. Total return includes dividends reinvested.

The closing share price for Zoetis Inc. (ZTS) stock was $82.20 for Tuesday, June 9, 2026, up +4.29% from the previous day.

ZTS Price Chart

End-of-day pricesAdvanced chart →
ZTS$82.20 -51.31%as of Jun 9, 2026

ZTS Earnings Preview

Next Earnings Date

Aug 4, 2026

56 days away

EPS Estimate

1.86

Revenue Est.

$2.50B

Last Quarter Results

EPS

$1.53

vs Estimate

$1.62

Missed

Revenue

$2.26B

vs Estimate

$2.30B

Missed

ZTS Analyst Ratings

Consensus Rating

Buy

Based on 17 analysts

Strong Buy
3
Buy
8
Hold
9
Sell
0
Strong Sell
0

Average Price Target

$124.59

+51.6% upside

Low

$90.00

Current

$82.20

High

$160.00

ZTS Analyst Estimates

Forward P/E: 11.08

Earnings Per Share (EPS) Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2027N/A$1.63N/A3
Q2 2027N/A$1.98N/A3
Q3 2027N/A$1.98N/A4
Q4 2027N/A$1.79N/A3

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$7.42N/A12
FY 2028N/A$8.02N/A6

Revenue Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2027N/A$2.35BN/A3
Q2 2027N/A$2.62BN/A3
Q3 2027N/A$2.62BN/A4
Q4 2027N/A$2.60BN/A3

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$10.17BN/A12
FY 2028N/A$10.67BN/A6

Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.

ZTS Competitors' Key Metrics

StockMarket CapClose PricePrice ChangeTTM Total Return5Y CAGR10Y CAGR
1ZTS$34.46B$82.20+4.29%-49.31%-13.32%+6.37%

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck